News about Industrial talks

Acute shortage of equipment faced by pharma companies and rise in APIs to affect drug availability during COVID: Infomerics

Indian vaccine manufacturers face a crucial shortage of equipment including small- and large-scale bioreactors and fermenters, a report "Pharma Industry: Trends and Prospects" from Infomerics Valuation and Rating revealed

Industrial talks | 30/08/2021 | By Darshana |  218

J B Chemicals to launch products in the area of anti-allergy, oral corticosteroids, cough & cold and nicotine replacement therapies

J B Chemicals & Pharmaceuticals stated that it will continue investing and strengthening portfolio in the cardiology and hypertension space and will continue to launch products in the area of anti-allergy, oral corticosteroids, cough & cold and nicotine replacement therapies

Industrial talks | 30/08/2021 | By Darshana |  582

Wockhardt arm partners with Jemincare for novel respiratory antibiotic nafithromycin

Wockhardt Bio AG - a subsidiary of Wockhardt Limited, a worldwide leader in discovery of novel antibiotics and Jiangxi Jemincare Group Company Limited, China, have partnered for Wockhardt's novel patented antibiotic WCK 4873 (nafithromycin) in People's Republic of China, Hong Kong, Macau and Taiwan for the treatment of community-acquired bacterial

Industrial talks | 26/08/2021 | By Darshana |  444

Vertex Pharma, Arbor enter new collaboration to develop novel ex vivo engineered cell therapies

Vertex Pharmaceuticals Incorporated, a global biotechnology company, and Arbor Biotechnologies (Arbor), an early-stage life sciences company, announced a new collaboration to enhance efforts in developing ex vivo engineered cell therapies, using Arbor's proprietary CRISPR gene-editing technology for select diseases

Industrial talks | 25/08/2021 | By Darshana |  383

FPME: Pharma exporters ignored under chapter 29 and 30 for RoDTEP rates

The Federation of Pharmaceutical Merchant Exporters and Allied Products (FPME) stated that pharmaceutical exporters are feeling neglected and taken for granted under Remission of Duties and Taxes on Exported Products (RoDTEP), as no rates were announced under chapter 29 and 30 by the Directorate General of Foreign Trade (DGFT)

Industrial talks | 24/08/2021 | By Darshana |  473

Serum Institute picks up 50% in glass vial maker Schott's Indian JV

Vaccine maker Serum Institute of India (SII) has picked up a 50 per cent stake in specialty glass company Schott AG's Indian joint venture, Schott Kaisha, from the former co-owners Kairus Dadachanji and Shapoor Mistry for an undisclosed sum

Industrial talks | 21/08/2021 | By Darshana |  682

F&S notes global medical imaging & informatics market thrives with AI and cloud to spur growth

Frost & Sullivan has noted that the healthcare sector's emphasis on meeting its Quadruple Aim goal of cost reduction, clinical outcomes, enhance the patient and caregiver experience, and improve the work-life of its medical professionals, nurses and paramedics encourages the medical imaging and informatics industry to use advanced technologies

Industrial talks | 12/08/2021 | By Darshana |  246

Cipla receives US FDA approval for generic Durezol

Cipla Limited has received final approval for its Abbreviated New Drug Application (ANDA) for difluprednate ophthalmic emulsion 0.05% from the United States Food and Drug Administration (FDA)

Industrial talks | 12/08/2021 | By Darshana |  228

IPC flags safety alerts against etoricoxib, torsemide and quetiapine & valproic acid interaction

The Indian Pharmacopoeia Commission (IPC) which is the National Coordination Centre (NCC) for Pharmacovigilance Programme of India (PvPI) has flagged safety alerts against etoricoxib, torsemide and quetiapine & valproic acid interaction.

Industrial talks | 09/08/2021 | By Darshana |  551

Kite inks research pact with Appia Bio to develop allogeneic cell therapies

Kite, a Gilead Company and Appia Bio, an early stage biotechnology company, announced a collaboration and license agreement to research and develop HSC-derived cell therapies directed toward hematological malignancies. Under the partnership, Kite and Appia Bio will develop chimeric antigen receptor

Industrial talks | 07/08/2021 | By Darshana |  199